Adverse Events and Failure Modes Related to Impella RP/RP Flex: Insights From FDA MAUDE Database
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Kalyan R Chitturi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, United States Food and Drug Administration, Prosthesis Failure, Ventricular Function, Right. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Impella RP and RP Flex can provide right ventricular (RV) support in numerous clinical situations. Notably, the redesigned RP Flex allows for an internal jugular approach compared to the femoral venous approach with RP.
Aims
We investigated the type and frequency of device‐related complications as reported in the US Food and Drug Administration (FDA) Manufacturer and User Facility Experience (MAUDE) for both Impella RP and RP Flex to see if there are any differences.
Methods
The MAUDE database was accessed from January 1, 2019 to April 30, 2024, yielding 206 reports pertaining to Impella RP and 64 to RP Flex. Reports were reviewed for device indications, mode of device failure, and device‐related complications.
Results
The most common indication for Impella RP placement was acute myocardial infarction with RV failure. The most commonly reported failure mode was pump failure. Death was reported in 8.5% and vascular complications in 3.7% of the reports. The most reported device‐related complication was hemolysis (18.5%), followed by bleeding requiring transfusion (14.1%), with new dialysis occurring in 3.3% of patients.
Conclusions
Our analysis of the MAUDE database showed that device delivery issues, bleeding, and vascular complications accounted for a smaller proportion of reports with Impella RP Flex than with its predecessor. However, device‐related thrombosis and pump malfunction accounted for a higher proportion of reports with RP Flex. These data do not reflect the overall incidence of complications, but instead highlight the need for physicians and other healthcare providers to return devices to the manufacturer for inspection when a failure occurs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
- Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
ORCID-Profile: Ryan Wallace, Ilan Merdler, Ron Waksman
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Chitturi, K. R., Wallace, R., Lorente-Ros, M., Merdler, I., Chaturvedi, A., Case, B. C., Hashim, H. D., Ben-Dor, I., Rogers, T., & Waksman, R. (2025). Adverse Events and Failure Modes Related to Impella RP/RP Flex: Insights From FDA MAUDE Database. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31333
Vancouver
Chitturi KR, Wallace R, Lorente-Ros M, Merdler I, Chaturvedi A, Case BC, et al. Adverse Events and Failure Modes Related to Impella RP/RP Flex: Insights From FDA MAUDE Database. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31333
BibTeX
@article{Chitturi2025,
author = {Chitturi, Kalyan R and Wallace, Ryan and Lorente-Ros, Marta and Merdler, Ilan and Chaturvedi, Abhishek and Case, Brian C and Hashim, Hayder D and Ben-Dor, Itsik and Rogers, Toby and Waksman, Ron},
title = {Adverse Events and Failure Modes Related to Impella RP/RP Flex: Insights From FDA MAUDE Database},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31333}
}
EUVIMED